Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1% – Here’s Why

by · The Markets Daily

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Get Free Report) fell 5.1% during trading on Monday. The company traded as low as $10.23 and last traded at $10.0960. Approximately 51,739 shares were traded during trading, a decline of 91% from the average daily volume of 592,301 shares. The stock had previously closed at $10.64.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Silence Therapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating for the company. Morgan Stanley boosted their target price on shares of Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.50.

Get Our Latest Stock Analysis on Silence Therapeutics

Silence Therapeutics Stock Performance

The business’s 50 day moving average is $12.68 and its two-hundred day moving average is $9.40. The firm has a market capitalization of $591.86 million, a PE ratio of -7.68 and a beta of 1.45.

Silence Therapeutics (NASDAQ:SLN – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. As a group, equities research analysts predict that Silence Therapeutics PLC Sponsored ADR will post -1.03 EPS for the current year.

Institutional Trading of Silence Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC grew its position in shares of Silence Therapeutics by 29.6% during the 2nd quarter. Squarepoint Ops LLC now owns 115,918 shares of the company’s stock valued at $1,273,000 after purchasing an additional 26,449 shares in the last quarter. AXQ Capital LP bought a new position in shares of Silence Therapeutics in the second quarter worth $138,000. 5AM Venture Management LLC purchased a new stake in shares of Silence Therapeutics in the second quarter worth $5,228,676. GAMMA Investing LLC raised its position in shares of Silence Therapeutics by 18.1% in the second quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock worth $121,000 after buying an additional 1,698 shares in the last quarter. Finally, Seven Fleet Capital Management LP boosted its stake in Silence Therapeutics by 6.2% during the first quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock valued at $826,000 after buying an additional 9,159 shares during the period. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

(Get Free Report)

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. The company’s approach is designed to act at the genetic level by targeting specific messenger RNA molecules before they are translated into proteins.

Silence’s research is supported by its proprietary mRNAi GOLD platform, which is intended to enable the development and delivery of small interfering RNA (siRNA) medicines.

Further Reading